Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients

Acta Neurologica Scandinavica

Volumn 107, Issue 4, 2003, Pages 252-255

  Fogelson, N ^a   Kogan, E ^b   Korczyn, Amos D ^a,b   Giladi, N ^b   Shabtai, H ^b   Neufeld, M Y ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cholinesterase inhibitors; Dementia; Parkinson's disease; Quantitative electroencephalogram; Rivastigmine

Indexed keywords

RIVASTIGMINE; TACRINE;

AGED; ALPHA RHYTHM; ANALYSIS OF VARIANCE; ARTICLE; BETA RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELTA RHYTHM; DEMENTIA; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; OPEN STUDY; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; THETA RHYTHM;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARBAMATES; CHOLINESTERASE INHIBITORS; DEMENTIA; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHENYLCARBAMATES;

EID: 0038702333     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.00081.x     Document Type: Article

References (17)

1. HOLSCHNEIDER DP, LEUCHTER AF. Clinical neurophysiology using electroencephalography in geriatric psychiatry: neurobiologic implications and clinical utility. J Geriatr Psychiatry Neurol 1999;12:150-64.
2. GILADI N, TREVES AT, PALEACU D et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 2000;107:59-71.
3. NEUFELD MY, BLUMEN S, AITKIN I, PARMET Y, KORCZYN AD. EEG frequency analysis in demented and nondemented parkinsonian patients. Dementia 1994;5:23-8.
4. NEUFELD MY, INZELBERG R, KORCZYN AD. EEG in demented and non-demented parkinsonian patients. Acta Neurol Scand 1988;78:1-5.
5. PRIMAVERA A, NOVELLO P. Quantitative electroencephalography in Parkinson's disease, dementia, depression and normal aging. Neuropsychobiology 1992;25:102-5.
6. SOIKKELI R, PARTANEN J, SOININEN H, PAAKKONEN A, RIEKKINEN P. Slowing of EEG in Parkinson's disease. Electroencephlogr Clin Neurophsiol 1991;79:159-65.
7. JANN MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 2000;20:1-12.
8. ROSLER M, ANAND R, CICIN-SAIN A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999;18:633-8.
9. MCKEITH I, DEL SER T, SPANO P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6.
10. PERRY EK, CURTIS M, DICK DJ et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413-21.
11. WHITEHOUSE PJ, HEDREEN JC, WHITE CL, PRICE DL. Basal forebrain neurons in the dementia of Parkinson's disease. Ann Neurol 1983;13:243-8.
12. HUTCHINSON M, FAZZINI E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:324-5.
13. GILADI N, SHABTAI H, GUREVICH T, BENBUNAN B, ANCA M, KORCZYN AD. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand (in press).
14. HUGHES A, DANIEL S, KILFORD L, LEES A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease - a clinico pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
15. ROSEN WG, MOHS RC, DAVIS KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
16. ALHAINEN K, PARTANEN J, REINIKAINEN K et al. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease. Neurosci Lett 1991;127:113-6.
17. ALHAINEN K, RIEKKINEN P. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand Suppl 1993;149:16-21.